Cardio Diagnostics (CDIO) Stock Price, News & Analysis

Company Overview

Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is headquartered in Chicago, Illinois.

Key Stats

• Today's Range: $3.37 to $3.93
• 50-Day Range: $3.28 to $4.99
• 52-Week Range: $3.22 to $53.10
• Volume: 72,559 shs
• Average Volume: 41,957 shs
• Market Capitalization: $6.00 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $60.00
• Consensus Rating: Buy

Cardio Diagnostics Stock Analysis - MarketRank™

Cardio Diagnostics scored higher than 51% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Cardio Diagnostics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Cardio Diagnostics has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Book Value per Share Ratio

Cardio Diagnostics has a P/B Ratio of 0.49. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.78% of the float of Cardio Diagnostics has been sold short.

Short Interest Ratio / Days to Cover

Cardio Diagnostics has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Cardio Diagnostics has recently decreased by 70.26%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Cardio Diagnostics does not currently pay a dividend.

Dividend Growth

Cardio Diagnostics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.78% of the float of Cardio Diagnostics has been sold short.

Short Interest Ratio / Days to Cover

Cardio Diagnostics has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Cardio Diagnostics has recently decreased by 70.26%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 2 news articles for Cardio Diagnostics this week, compared to 0 articles on an average week.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Cardio Diagnostics insiders have not sold or bought any company stock.

Percentage Held by Insiders

22.30% of the stock of Cardio Diagnostics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 8.06% of the stock of Cardio Diagnostics is held by institutions.

CDIO Stock Analysis - Frequently Asked Questions

How have CDIO shares performed this year?

Cardio Diagnostics' stock was trading at $27.51 at the start of the year. Since then, CDIO stock has decreased by 87.5% and is now trading at $3.45.

How were Cardio Diagnostics' earnings last quarter?

Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) released its earnings results on Thursday, May, 15th. The company reported ($0.97) EPS for the quarter, missing analysts' consensus estimates of ($0.06) by $0.91. The firm had revenue of $0 million for the quarter, compared to analyst estimates of $0.05 million. Cardio Diagnostics had a negative net margin of 28,539.39% and a negative trailing twelve-month return on equity of 84.55%.

When did Cardio Diagnostics' stock split?

Cardio Diagnostics shares reverse split on Tuesday, May 13th 2025.The 1-30 reverse split was announced on Thursday, May 8th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Monday, May 12th 2025. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

Who are Cardio Diagnostics' major shareholders?

Cardio Diagnostics' top institutional shareholders include Geode Capital Management LLC (0.77%). Insiders that own company stock include Robert Philibert and Meeshanthini Dogan.
View institutional ownership trends.

How do I buy shares of Cardio Diagnostics?

Shares of CDIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Cardio Diagnostics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Cardio Diagnostics investors own include Sangamo Therapeutics (SGMO), NVIDIA (NVDA), MSP Recovery (LIFW), NuCana (NCNA), Recursion Pharmaceuticals (RXRX), SoundHound AI (SOUN) and Caribou Biosciences (CRBU).

Company Calendar

• Last Earnings: 5/15/2025
• Today: 8/11/2025
• Next Earnings (Estimated): 8/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CDIO
• CIK: 1870144
• Web: cardiodiagnosticsinc.com
• Phone: 302-281-2147
• Fax: N/A
• Employees: 1
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Cardio Diagnostics: $60.00
• High Price Target: $60.00
• Low Price Target: $60.00
• Potential Upside/Downside: +1,639.1%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$8.38 million
• Net Margins: -28,539.39%
• Pretax Margin: -28,539.39%
• Return on Equity: -84.55%
• Return on Assets: -74.63%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 19.47
• Quick Ratio: 19.47

Sales & Book Value

• Annual Sales: $40 thousand
• Price / Sales: 150.08
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $7.10 per share
• Price / Book: 0.49

Miscellaneous

• Outstanding Shares: 1,740,000
• Free Float: 1,351,000
• Market Cap: $6.00 million
• Optionable: Not Optionable
• Beta: 2.96